Drug development company barriers

These two considerations have not declined in importance with time. As medicines inexorably climb in price over the rate of inflation and less westernized countries develop pharmaceutical industries, admittedly small compared to the financial magnitude of major western companies, western governments are caught between two conflicting interests. The interest of the citizen who cannot access the medicines they need and the western pharmaceutical companies fear that competition will prevent annual record profits. To relinquish the pharmaceutical product patent will reduce barriers to market entry, facilitating competition and leading to lower drug prices at home and abroad. 

Because of increased difficulty in getting a new drug on an MCO s formulary, it is now common for pharmaceutical companies to collaborate with managed care decision makers in round table or advisory board meetings. These discussions, which normally occur before product launch or as early as phases II and III of clinical development, are helpful in determining reimbursement status and identifying potential barriers and restrictions that may be placed on the product, once approved. 

---